The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod ...

Key highlights from the Type C FDA meeting include: FDA confirms the approach that the proposed primary endpoint of the Visual Analogue Scale (VAS) pain reduction at Week 12 is clinically meaningful, ...

Under the FDA-authorized expanded access (IND 176297), urcosimod is being provided by OKYO Pharma for use in a patient with severe neuropathic corneal pain who has limited therapeutic options and no ...

An expanded clinical trial that tested an experimental stem cell treatment for blinding cornea injuries found the treatment was feasible and safe in 14 patients who were treated and followed for 18 ...